NCT02308202

DOXAZOSIN FOR PTSD

DOXAZOSIN AS A TREATMENT FOR POST TRAUMATIC STRESS SYNDROME

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Baylor College of Medicine · Academic / Other
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

The aims of this study is to determine the effects of treatment with doxazosin XL 16 mg/d combined with virtual reality (VR) exposure therapy on Post Traumatic Stress Disorder. The effects of treatment with doxazosin XL 16 mg/d combined with virtual reality (VR) exposure therapy will be assessed in double-blind, placebo-controlled study. The study will enroll 30 participants. The investigators will use a within groups design in which all participants receive both placebo and doxazosin (N=16) with the order counterbalanced across participants. A second group of patients (N=16) will receive both 16mg perindopril and placebo instead of doxazosin/placebo.

Conditions

• PTSD

Interventions

Type	Name	Description
DRUG	doxazosin
DRUG	Perindopril
DRUG	Placebo

Timeline

• Start date: 2012-01-01
• Primary completion: 2014-06-30
• Completion: 2014-06-30
• First posted: 2014-12-04
• Last updated: 2022-04-26

Locations

1 site across 1 country: United States